Avalo Therapeutics, Inc. · NASDAQ:AVTX

Doyle Mittie sold 3,000 Avalo Therapeutics, Inc. shares (Form 4)

Traded May 15, 2026 · Filed May 19, 2026

On May 15, 2026, Doyle Mittie (Chief Medical Officer) sold 3,000 Avalo Therapeutics, Inc. shares at US$18.76 for US$56,280 under a trading plan, leaving 3,622 shares. Filed May 19, 2026 (Form 4).

Sold
3,000 shares
Price
US$18.76
Value
US$56,280
Holding after
3,622 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Medical Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
May 15, 2026Common StockOption exercise3,000US$12.656,622Direct
May 15, 2026Common StockSale3,000US$18.763,622Direct

Source

View original at SEC

Related